ACROBiosystems, a global biotechnology company advancing drug development through innovative tools and solutions, has signed a strategic Memorandum of Understanding (MoU) with DAAN Biotherapeutics, a clinical-stage biotech focused on precision immuno-oncology.
The collaboration framework includes a stable supply of high-performance bioreagents, joint technical cooperation in immuno-oncology drug development, and shared research and data. The partnership aims to accelerate the development and commercialization of next-generation precision immunotherapies.
ACROBiosystems provides recombinant proteins, kits, antibodies, and scientific services, addressing key challenges in cell and gene therapy (CGT) through its Resilient Supply™ platform. With a GMP-certified modular manufacturing base, the company ensures flexible large-scale production of raw materials while maintaining global compliance to support biopharma innovation.
DAAN Biotherapeutics is building a proprietary immune-modulation platform that selectively activates T cells within the tumor microenvironment. By precisely tuning T-cell activation, the platform overcomes toxicity and resistance issues linked to conventional immunotherapies, enhancing safety and efficacy. Beyond oncology, DAAN is expanding applications to autoimmune and rare diseases, with its lead pipeline preparing for entry into global clinical trials.
Byoung Chul Cho, CEO of DAAN Biotherapeutics, commented, "ACROBiosystems is a trusted partner with a quality-focused philosophy and technological innovation capabilities. This collaboration will not only enhance our efficiency in transitioning from preclinical to clinical development but also accelerate our entry into global clinical trials."
Yong Chan Cho, Country Manager of ACROBiosystems Korea, added, "This collaboration with DAAN Biotherapeutics, which possesses unparalleled technological expertise in the field of immuno-oncology, marks a highly meaningful strategic milestone. We expect this partnership to generate positive synergies not only in precision therapeutics but also across the broader Korean biotech industry."